为么顶级疾控专家亦逃不外胰腺癌？！这项连续了25年的科研，揭示怎么样超初期诊断、大幅加强存活率
<strong style="color: blue;"><strong style="color: blue;"><span style="color: black;"><strong style="color: blue;"><strong style="color: blue;"><span style="color: black;"><strong style="color: blue;"><strong style="color: blue;"><span style="color: black;"><strong style="color: blue;"><strong style="color: blue;"><span style="color: black;"><strong style="color: blue;"><strong style="color: blue;">Bringing medical advances from the lab to the clinic.</strong></strong></span></strong></strong></span></strong></strong></span></strong></strong></span></strong></strong><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">重要</span>词</span></strong></span><span style="color: black;">：胰腺癌；SCI论文；Healsan大数据</span><span style="color: black;">2023年10月27日<span style="color: black;">晌午</span>，知名流行病学家、中国疾控中心流行病学首席专家吴尊友因病去世，享年60岁。</span><span style="color: black;">海外<span style="color: black;">媒介</span><span style="color: black;">亦</span>做了<span style="color: black;">海量</span>报告，题目给出了<span style="color: black;">没</span>一例外的身份定义：<strong style="color: blue;">流行病学专家</strong></span><span style="color: black;">。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhGyOqLxDlmibYZBFZiaPlXMOcvOEa8fy08MqdaiacAWhIqm2WficU39WtDg/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（海外<span style="color: black;">媒介</span>的报告）</span><span style="color: black;">打开吴尊友博士的<span style="color: black;">博客</span>【1】，最后一条为：较真于<strong style="color: blue;">戴口罩是科学问题、<span style="color: black;">亦</span>是管理问题。</strong></span><img src="https://mmbiz.qpic.cn/mmbiz_jpg/gibznY273KftH6E6obyX9pgAb3sj5W3NhbiaJPynn89tVtwYD9UAJJhSelOfmldvq7C4x9ZKtyHdnRj4ia4xEFYjQ/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">哀思</span>之余，<span style="color: black;">非常多</span><span style="color: black;">伴侣</span><span style="color: black;">亦</span>在问：到底是什么<span style="color: black;">疾患</span>，夺走了年仅60岁<span style="color: black;">疾患</span>预防的首席专家的生命？</p>
</span><span style="color: black;">维基百科：<span style="color: black;"><strong style="color: blue;">胰腺癌</strong></span></span><span style="color: black;"><strong style="color: blue;">一，癌症之王：胰腺癌</strong></span><span style="color: black;">胰腺癌<span style="color: black;">由于</span>其极低的5年<span style="color: black;">存活</span>率而让人<span style="color: black;">毛骨悚然</span>。</span><span style="color: black;">即使在科技快速发展的今天、即使<strong style="color: blue;">在美国，其五年<span style="color: black;">存活</span>率<span style="color: black;">亦</span><span style="color: black;">刚才</span>达到了12%</strong>；是<span style="color: black;">存活</span>率最低的癌症类型。<span style="color: black;">亦</span>由此被<span style="color: black;">叫作</span>为“癌症之王”。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3Nh3Nhwu3xMsSaMjmo1HPJdJPdGvytKwODkbHtQl6PLgnKPmDnXbAaLaQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（美国癌症协会年报）</span><span style="color: black;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">亦</span>由此，胰腺癌仅占所有癌症发病的3%，却占死亡比例的8%。</p>
</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3Nh3J6Eic0Glct2DtE44hlZUYTK7IlLJRshncBDhuicOicg4Wd07BFib7fhiaw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">胰腺癌的<span style="color: black;">存活</span>率低有多个<span style="color: black;">原由</span>：</span></strong></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">1）晚期诊断：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">胰腺癌在<span style="color: black;">初期</span><span style="color: black;">常常</span>不产生<span style="color: black;">显著</span>症状，<span style="color: black;">或</span>其症状与其他消化系统<span style="color: black;">疾患</span><span style="color: black;">类似</span>，如消化不良、胃痛等。<span style="color: black;">因此呢</span>，当<span style="color: black;">病人</span><span style="color: black;">显现</span><span style="color: black;">显著</span>症状并被诊断为胰腺癌时，肿瘤<span style="color: black;">常常</span><span style="color: black;">已然</span><span style="color: black;">发展</span>到中晚期，<span style="color: black;">乃至</span><span style="color: black;">已然</span><span style="color: black;">出现</span>转移。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2）肿瘤的生物学特性：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">胰腺癌的细胞<span style="color: black;">拥有</span><span style="color: black;">剧烈</span>的侵袭性和转移能力。<span style="color: black;">另外</span>，胰腺癌的微环境<span style="color: black;">常常</span>对化疗<span style="color: black;">药品</span>形成较强的抵抗。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3）治疗挑战：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">因为</span>胰腺在腹腔的位置较深，手术切除胰腺癌<span style="color: black;">拥有</span><span style="color: black;">必定</span>的困难。<span style="color: black;">同期</span>，胰腺癌对多种常用的化疗<span style="color: black;">药品</span>反应较差。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">4）缺乏<span style="color: black;">初期</span>筛查<span style="color: black;">办法</span>：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>尚缺乏有效、简便和经济的<span style="color: black;">办法</span>来进行胰腺癌的<span style="color: black;">初期</span>筛查。</span></p><span style="color: black;"><span style="color: black;">由于</span>胰腺癌对人类健康的<span style="color: black;">极重</span><span style="color: black;">损伤</span>，<span style="color: black;">亦</span><span style="color: black;">作为</span><span style="color: black;">大夫</span><span style="color: black;">专家</span><span style="color: black;">科研</span>的重点，<span style="color: black;">咱们</span>关注的焦点之一。</span><span style="color: black;"><span style="color: black;">实质</span>上，在过去的一年里，不管是超<span style="color: black;">初期</span>诊断<span style="color: black;">科研</span>、还是治疗<span style="color: black;">科研</span>，在胰腺癌<span style="color: black;">行业</span>都有了突破性<span style="color: black;">发展</span>。</span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">Nature：确认胰腺癌细胞独特</strong></a><strong style="color: blue;">的代谢途径，突破性治疗显现曙光</strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;"><strong style="color: blue;">JCO：20余年不懈改良，最新的个体化筛查<span style="color: black;">方法</span>将“癌症之王”的5年<span style="color: black;">存活</span>率<span style="color: black;">加强</span>到73%！</strong></span></a></p><span style="color: black;">为推动在胰腺癌<span style="color: black;">行业</span>的临床<span style="color: black;">研究</span>，本文</span><span style="color: black;"><span style="color: black;">经过</span>对<span style="color: black;">近期</span>三年胰腺癌<span style="color: black;">科研</span><span style="color: black;">行业</span>SCI的大数据分析，找到</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">胰腺癌<span style="color: black;">科研</span>热点、热门期刊、</span><span style="color: black;">最活跃的<span style="color: black;">科研</span><span style="color: black;">公司</span>/<span style="color: black;">科研</span>人员，以及美国<span style="color: black;">日前</span><span style="color: black;">这里</span><span style="color: black;">行业</span>的<span style="color: black;">帮助</span><span style="color: black;">状况</span></span></strong></span><span style="color: black;">。</span><span style="color: black;"><strong style="color: blue;">检索数据库：</strong>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Medline</p>
</span><span style="color: black;"><strong style="color: blue;">检索<span style="color: black;">工具</span>：</strong><strong style="color: blue;"><span style="color: black;">Healsan大数据</span></strong></span><span style="color: black;"><strong style="color: blue;">检索时间：</strong>October 27, 2023</span><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">检索及分析<span style="color: black;">公司</span>：</span></strong></span><span style="color: black;">Healsan Consulting LLC（美国恒祥咨询）</span></span><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">检索内容：</span></strong></span><span style="color: black;">2020年1月1日之后<span style="color: black;">发布</span>的论文</span></span><span style="color: black;"><strong style="color: blue;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">二，<span style="color: black;">科研</span>胰腺癌最活跃的<span style="color: black;">公司</span>和<span style="color: black;">大夫</span><span style="color: black;">专家</span></p>
</strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">胰腺癌</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">论文的</span></strong></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">时间和国家分布</span></strong></span><span style="color: black;"><span style="color: black;">近期</span>3年，<span style="color: black;">全世界</span><span style="color: black;">已然</span>在</span><strong style="color: blue;"><span style="color: black;">胰腺癌</span></strong><span style="color: black;"><span style="color: black;">行业</span>发表了20,217篇Medline收录的文献，年<span style="color: black;">发帖</span>量超过5000篇。</span><span style="color: black;"><span style="color: black;">发帖</span>量最多的国家依次为：美国、中国、日本、意大利和德国。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhsG6ib8Vhibxia4dHF8tPxSYPP3n7sNAatibJR1l354V2uanhjribQiajfxSg/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（SCI论文的时间和国家分布）</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">学术<span style="color: black;">公司</span>排名</span></strong></span><span style="color: black;"><span style="color: black;">根据</span><span style="color: black;">发布</span>的SCI论文累计影响因子排名，最高的医院依次为：</span><strong style="color: blue;"><span style="color: black;">美国的MD Anderson癌症中心、美国的纪念斯隆凯特琳癌症中心、中国的北京协和医院、中国的复旦大学<span style="color: black;">附庸</span>肿瘤医院、美国的内布拉斯加大学医学中心</span></strong><span style="color: black;">。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhxiaIGnHmnzeWCQGWicI5cTy7GL4fpOeBXefs9OuWulHfTdD47ofxCDrQ/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（<span style="color: black;">全世界</span><span style="color: black;">发布</span>论文累计影响因子最高的医院排名）</span><strong style="color: blue;"><span style="color: black;"><span style="color: black;">科研</span><span style="color: black;">发布</span>在<span style="color: black;">那些</span>杂志？</span></strong><span style="color: black;"><span style="color: black;"><span style="color: black;">能够</span>看到<span style="color: black;">近期</span>3年，<span style="color: black;">发布</span>胰腺癌<span style="color: black;">关联</span><span style="color: black;">科研</span>最多的五个杂志是</span>Cancers (Basel), Front Oncol, Ann Surg Oncol， Pancreas，Pancreatology<span style="color: black;">等专业期刊。</span></span><span style="color: black;">杂志后面附有影响因子，参考这个排名及影响因子，<span style="color: black;">针对</span>投稿有非常强的参考价值。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhDNd3zVpwxTibaNicjsibiay9eCMAUawgKkgLBRXpfA4NpG0icGkIr4Yx3fw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（<span style="color: black;">发布</span>论文的杂志分布）</span><span style="color: black;"><strong style="color: blue;">最有影响力学者</strong></span><span style="color: black;">及其关系网。</span><span style="color: black;">国际</span><span style="color: black;"><strong style="color: blue;">胰腺癌</strong></span><span style="color: black;"><span style="color: black;">科研</span>论文中最有影响力的学者如下图所示。</span><span style="color: black;"><span style="color: black;">能够</span>看到胰腺癌的学者们联系并不紧密。<span style="color: black;">非常多</span>时候这<span style="color: black;">寓意</span>着在该<span style="color: black;">行业</span>的临床<span style="color: black;">实验</span>开展的比较少。</span><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhdWgEUl2XfH57d7pwAZ9iaFVibdEMFlkEMgxQyavCE9xzUz7153iaHo3ow/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;">（学术大咖及其关系网。）</span><span style="color: black;"><strong style="color: blue;">学者影响力</strong></span><span style="color: black;">是基于<strong style="color: blue;">学者在该<span style="color: black;">行业</span>的</strong></span><strong style="color: blue;">论文影响因子总分</strong><span style="color: black;"><span style="color: black;">能够</span>看到，美国纪念斯隆凯特琳癌症中心的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">OReilly, Eileen M</span></strong></span><span style="color: black;">、中国北京协和医院的<span style="color: black;"><strong style="color: blue;">Zhao, Yupei</strong></span>、中国浙江大学医学院<span style="color: black;">附庸</span><span style="color: black;">第1</span>医院的<span style="color: black;"><strong style="color: blue;">Liang, Tingbo</strong></span>、美国MD Anderson癌症中心的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Maitra, Anirban</span></strong></span><span style="color: black;">、美国Perlmutter癌症中心的</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Kimmelman, Alec C</span></strong></span><span style="color: black;">、中国瑞金医院的<span style="color: black;"><strong style="color: blue;">Shen, Baiyong</strong></span>等在胰腺癌的<span style="color: black;">科研</span><span style="color: black;">行业</span>最为活跃。</span><img src="https://mmbiz.qpic.cn/mmbiz_jpg/gibznY273KftH6E6obyX9pgAb3sj5W3NhMplGZicz4nJox14eib79ne6pU3zEfNLCs1pC50IMAz1rOFH00cWIibGHw/640?wx_fmt=jpeg&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhMgYjYKSBb8Ij5mCZunyaWQUIQClbZZgVeTfsndiaTicKcRdpVIuSsbzA/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"><span style="color: black;"><strong style="color: blue;">三，胰腺癌的<span style="color: black;">科研</span>热点</strong></span><strong style="color: blue;"><span style="color: black;">1，胰腺癌<span style="color: black;">科研</span>的热门基因</span></strong><span style="color: black;"><span style="color: black;">近期</span>三年，在胰腺癌<span style="color: black;">行业</span><span style="color: black;">科研</span>最受关注的基因<span style="color: black;">包含</span>：KRAS, MTOR, STAT3, EGFR, SMAD4等。</span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">1）KRAS：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">KRAS是胰腺癌中最<span style="color: black;">平常</span>的突变基因。大约90%的胰腺导管腺癌（最<span style="color: black;">平常</span>的胰腺癌类型）中都存在KRAS的激活突变。这种突变<span style="color: black;">引起</span>细胞增殖的信号<span style="color: black;">连续</span>激活，从而促进癌症的发展。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2）mTOR：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">mTOR是一个<span style="color: black;">重要</span>的细胞增殖和<span style="color: black;">存活</span>信号通路的调节因子。它在胰腺癌中的激活可能会促进肿瘤生长。靶向mTOR的<span style="color: black;">药品</span>正在被<span style="color: black;">科研</span><span style="color: black;">做为</span>胰腺癌的治疗策略。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">3）STAT3：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">STAT3是一个转录因子，参与多种细胞信号通路，<span style="color: black;">尤其</span>是与细胞生长和<span style="color: black;">存活</span><span style="color: black;">相关</span>的信号通路。在胰腺癌中，STAT3的激活与恶性表型、增殖和抗凋亡<span style="color: black;">关联</span>。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">4）EGFR (表皮生长因子受体)：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">EGFR在许多肿瘤中都被过度表达或激活，<span style="color: black;">包含</span>胰腺癌。EGFR的激活<span style="color: black;">能够</span>促进细胞增殖、侵袭和迁移。靶向EGFR的治疗策略，如厄洛替尼（Erlotinib），<span style="color: black;">已然</span>被用于胰腺癌的治疗。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">5）SMAD4：</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">SMAD4是TGF-β信号通路中的一个<span style="color: black;">重要</span>因子。在胰腺癌中，SMAD4的失活突变是<span style="color: black;">平常</span>的，并与<span style="color: black;">疾患</span>的<span style="color: black;">发展</span>和预后不良<span style="color: black;">相关</span>。</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhdricSWiczqn8AUKJ7kibL5z4pQLVibPGBfbMvJXTnrQicYSzAdiamnB6hTeg/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">行业</span>内的经典论文</strong></span><span style="color: black;"><span style="color: black;">近期</span>3年，胰腺癌<span style="color: black;">行业</span>被引用最多的论文如下列表，这些论文<span style="color: black;">重点</span>是胰腺癌的</span><span style="color: black;"><strong style="color: blue;">病理生理<span style="color: black;">科研</span>、T细胞<span style="color: black;">要求</span>、新抗原、新辅助治疗和临床<span style="color: black;">实验</span></strong></span><span style="color: black;"><span style="color: black;">科研</span>。</span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhQibyOZl9yUja8TOqp8VX38nJXaNUUsktGyiaMevlXgvKOhLSJNgWyWMA/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;"><strong style="color: blue;">在胰腺癌<span style="color: black;">行业</span></strong></span><span style="color: black;"><strong style="color: blue;">
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">美国在研课题速览</p>
</strong></span><span style="color: black;">在胰腺癌<span style="color: black;">科研</span>中，美国NIH<span style="color: black;">日前</span><span style="color: black;">帮助</span>的在研课题有420项，<span style="color: black;">科研</span><span style="color: black;">行业</span><span style="color: black;">重点</span>集中在肿瘤微环境、靶向治疗（遗传学、表观遗传、异质性、KRAS等）、T细胞<span style="color: black;">干涉</span>（CAR T、CD8+ T等），以及<span style="color: black;">初期</span>诊断、<span style="color: black;">存活</span>率和临床<span style="color: black;">实验</span>等。<span style="color: black;">日前</span>在研的基金<span style="color: black;"><span style="color: black;">帮助</span>金额就达1.78亿美元。</span></span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/gibznY273KftH6E6obyX9pgAb3sj5W3NhuKXQkOibDUkDuGO4ZQib051eP9xLuSJD8HZmc7LZT23BciaAMYHzZdEicw/640?wx_fmt=png&tp=webp&wxfrom=5&wx_lazy=1&wx_co=1" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;"><strong style="color: blue;">展望：</strong></span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">痛定思痛，期待在胰腺癌<span style="color: black;">科研</span>者有<span style="color: black;">更加多</span>投入。</p><span style="color: black;">同期</span>，<span style="color: black;">咱们</span><span style="color: black;">亦</span>看到了在胰腺癌超<span style="color: black;">初期</span>诊断中的突破：<span style="color: black;"><strong style="color: blue;"><span style="color: black;">2022年10月</span></strong><span style="color: black;">，</span></span><span style="color: black;"><strong style="color: blue;">J Clin Oncol</strong></span><span style="color: black;"><span style="color: black;">发布</span>了一篇来自<span style="color: black;"><strong style="color: blue;">美国约翰·霍普金斯</strong></span>的<span style="color: black;">科研</span>论文，<span style="color: black;">科研</span><span style="color: black;">发掘</span>：<span style="color: black;">经过</span>20余年的<span style="color: black;">连续</span>改良，其个体化筛查<span style="color: black;">方法</span>对胰腺癌<span style="color: black;">知道</span>高危人群进行常规筛查（CAPS5），能</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">加强</span>Stage I胰腺癌<span style="color: black;">发掘</span>率，<span style="color: black;">从而</span>会<span style="color: black;">明显</span><span style="color: black;">加强</span><span style="color: black;">病人</span>5年<span style="color: black;">存活</span>率到73.3%。</strong></span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><strong style="color: blue;">JCO：20余年不懈改良，最新的个体化筛查<span style="color: black;">方法</span>将“癌症之王”的5年<span style="color: black;">存活</span>率<span style="color: black;">加强</span>到73%！</strong></a></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">2023年3月29日</span></strong></span><span style="color: black;">，</span><span style="color: black;"><span style="color: black;"><strong style="color: blue;">哈佛医学院</strong></span></span><span style="color: black;">在</span><span style="color: black;"><strong style="color: blue;">Nature</strong></span><span style="color: black;"><span style="color: black;">发布</span>了针对胰腺癌治疗的突破性<span style="color: black;">科研</span>，</span><span style="color: black;"><span style="color: black;">科研</span>人员<span style="color: black;">发掘</span>，胰腺癌细胞<span style="color: black;">经过</span>一种不寻常的途径产生必需的营养物质，这种途径可用于杀死癌细胞而不<span style="color: black;">损伤</span>健康组织。</span><span style="color: black;">这<span style="color: black;">显示</span>该途径可能是一种特异性靶向胰腺癌的<span style="color: black;">办法</span>。</span><a style="color: black;"><span style="color: black;"><strong style="color: blue;">Nature：确认胰腺癌细胞独特的代谢途径，突破性治疗显现曙光</strong></span></a><strong style="color: blue;"><span style="color: black;">期待人类<span style="color: black;">早点</span><span style="color: black;">解决</span>胰腺癌这个可怕的癌症。</span></strong>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">参考文献：</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">【1】 https://www.weibo.com/u/2351214845</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">【2】 https://zh.wikipedia.org/zh-hans/%E5%90%B4%E5%B0%8A%E5%8F%8B</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">扩展阅读：</span></strong></span><a style="color: black;"><span style="color: black;"><strong style="color: blue;"> 对于这个问题，我有不同的看法... 你的见解真是独到，让我受益匪浅。 谢谢、感谢、感恩、辛苦了、有你真好等。
页:
[1]